Susquehanna International Group, LLP Beam Therapeutics Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $36,112 - $53,024	1,600 Added 1.44%	112,700 $2.76 Million
Q2 2024 Aug 15, 2024	SELL	$21.22 - $32.66 $2.17 Million - $3.34 Million	-102,400 Reduced 47.96%	111,100 $2.6 Million
Q1 2024 May 07, 2024	BUY	$23.46 - $45.07 $3.86 Million - $7.42 Million	164,600 Added 336.61%	213,500 $7.05 Million
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $3.24 Million - $5.63 Million	-183,100 Reduced 78.92%	48,900 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $4.15 Million - $5.86 Million	180,400 Added 349.61%	232,000 $5.58 Million
Q2 2023 Aug 11, 2023	SELL	$29.32 - $35.99 $5.59 Million - $6.86 Million	-190,700 Reduced 78.7%	51,600 $1.65 Million
Q1 2023 May 16, 2023	BUY	$30.15 - $48.79 $3.81 Million - $6.16 Million	126,300 Added 108.88%	242,300 $7.42 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $2.19 Million - $3.08 Million	59,600 Added 105.67%	116,000 $4.54 Million
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $3.2 Million - $5.65 Million	-80,400 Reduced 58.77%	56,400 $2.69 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.69B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.